Clinical Trial Update: Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating spironolactone in combination with patiromer for resistant hypertension in chronic kidney disease; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperkalemia
• Resistant Hypertension

Drugs mentioned

• Patiromer (patiromer)
• Spironolactone (spironolactone)

Snippet

Sponsor: Relypsa, Inc. | Conditions: Hyperkalemia, Resistant Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-01-27